Literature DB >> 10846712

[Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].

U Künstler1, K Hohdorf, R Regenthal, A Seese, H J Gertz.   

Abstract

Beside the typical extrapyramidal motor symptoms such as rigidity, tremor, and dyskinesia, a reduction in handwriting area may occur under neuroleptic therapy. To date, the nature of the relationship between a reduction in handwriting area and striatal D2 dopamine receptor occupancy has remained unclear, and it is not known whether such a reduction also occurs under treatment with atypical neuroleptic drugs. In 23 schizophrenic patients treated with haloperidol, haloperidol decanoate, risperidone, and clozapine, the handwriting are was examined using a planimetric computer program. 123I-iodobenzamide (IBZM) single photon emission tomography (SPET) was used to measure the D2 dopamine receptor occupancy. A statistically significant correlation was found between a reduction in handwriting area and D2 dopamine receptor occupancy (r = 0.86; P < 0.0001). The curve derived from the plotted data resulted in a hyperbolic function. The regression was present regardless of whether the patients were treated with typical or atypical neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846712     DOI: 10.1007/s001150050571

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  2 in total

1.  Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.

Authors:  Michael P Caligiuri; Hans-Leo Teulings; Charles E Dean; Alexander B Niculescu; James B Lohr
Journal:  Psychiatry Res       Date:  2010-04-09       Impact factor: 3.222

2.  Handwriting movements for assessment of motor symptoms in schizophrenia spectrum disorders and bipolar disorder.

Authors:  Yasmina Crespo; Antonio Ibañez; María Felipa Soriano; Sergio Iglesias; Jose Ignacio Aznarte
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.